Durect Corporation is a biopharmaceutical company focused on developing innovative therapeutics based on its proprietary drug delivery technology platforms. The company specializes in formulating and delivering advanced medicines with an emphasis on treating chronic pain, liver diseases, and various central nervous system disorders. Durect's pipeline includes both proprietary drug candidates and partnerships that leverage its expertise in drug formulation and delivery systems, aimed at improving patient outcomes and enhancing the efficacy of existing therapies. Through its research and development efforts, Durect seeks to address significant unmet medical needs with its advanced drug delivery solutions. Read More
LAVAL, QC AND CUPERTINO, CA / ACCESS Newswire / August 26, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and DURECT Corporation (NASDAQ:DRRX) today announced that BHC Lyon Merger Sub, Inc. ("Purchaser"), a wholly owned subsidiary of Bausch Health Americas, Inc. ("BHA"), and an indirect subsidiary of Bausch Health Companies Inc. ("BHC"), has extended the expiration date of its tender offer (the "Offer") to acquire all of the outstanding shares of common stock of DURECT Corporation for $1.75 per share in an all-cash transaction for an upfront consideration of approximately $63 million at closing, with the potential for two additional net sales milestone payments of up to $350 million in the aggregate (subject to certain adjustments in respect of a retention plan) if the milestones are achieved before the earlier of the 10 year anniversary of the first commercial sale of larsucosterol (5-cholesten-3ß, 25-diol 3-sulfate sodium salt) in the United States and December 31, 2045.
Specificity Inc. (OTCID: SPTY), a next-generation digital marketing firm, has regained its status as a fully reporting SEC current filer—marking a key milestone as it continues to revolutionize audience targeting across digital platforms. Known for eliminating bots and irrelevant impressions, Specificity’s proprietary ad tech delivers precision-targeted ads across display, social, and Connected TV (CTV) to the same verified, high-intent audiences —maximizing ROI and minimizing waste.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of DURECT Corporation (NASDAQ: DRRX) to Bausch Health Companies Inc. for $1.75 per share is fair to DURECT shareholders.
The Ademi Firm is investigating DURECT (NYSE: DRRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Bausch Health.
